Jason Cole Sells 4,930 Shares of bluebird bio Inc (BLUE) Stock

bluebird bio Inc (NASDAQ:BLUE) insider Jason Cole sold 4,930 shares of the business’s stock in a transaction dated Thursday, March 16th. The stock was sold at an average price of $100.07, for a total transaction of $493,345.10. Following the transaction, the insider now owns 16,981 shares in the company, valued at $1,699,288.67. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Jason Cole also recently made the following trade(s):

  • On Wednesday, February 15th, Jason Cole sold 666 shares of bluebird bio stock. The shares were sold at an average price of $80.22, for a total transaction of $53,426.52.
  • On Tuesday, February 14th, Jason Cole sold 3,772 shares of bluebird bio stock. The shares were sold at an average price of $80.01, for a total transaction of $301,797.72.
  • On Thursday, January 5th, Jason Cole sold 549 shares of bluebird bio stock. The shares were sold at an average price of $67.10, for a total transaction of $36,837.90.

Shares of bluebird bio Inc (NASDAQ:BLUE) traded down 0.97% during midday trading on Monday, reaching $91.50. 654,428 shares of the company traded hands. The company’s 50 day moving average is $81.50 and its 200-day moving average is $67.35. The stock’s market capitalization is $3.74 billion. bluebird bio Inc has a 12 month low of $35.37 and a 12 month high of $100.40.

bluebird bio (NASDAQ:BLUE) last issued its quarterly earnings results on Wednesday, February 22nd. The company reported ($1.88) EPS for the quarter, missing analysts’ consensus estimates of ($1.86) by $0.02. The firm had revenue of $1.55 million for the quarter, compared to analysts’ expectations of $1.76 million. bluebird bio had a negative return on equity of 30.79% and a negative net margin of 3,941.72%. The business’s quarterly revenue was up 5.4% compared to the same quarter last year. During the same quarter last year, the firm earned ($1.29) earnings per share. Equities research analysts forecast that bluebird bio Inc will post ($7.31) earnings per share for the current fiscal year.

Insider Buying and Selling by Quarter for bluebird bio (NASDAQ:BLUE)

Your IP Address:

Several equities analysts have weighed in on the stock. Roth Capital set a $87.00 target price on shares of bluebird bio and gave the company a “buy” rating in a report on Thursday, December 1st. Jefferies Group LLC set a $88.00 target price on shares of bluebird bio and gave the company a “buy” rating in a report on Thursday, December 1st. BMO Capital Markets set a $83.00 target price on shares of bluebird bio and gave the company a “hold” rating in a report on Thursday, December 1st. Maxim Group boosted their target price on shares of bluebird bio from $57.00 to $87.00 and gave the company a “buy” rating in a report on Thursday, December 1st. Finally, Wedbush reiterated an “outperform” rating and issued a $95.00 target price on shares of bluebird bio in a report on Thursday, December 1st. One analyst has rated the stock with a sell rating, seven have assigned a hold rating and eleven have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $84.53.

Several large investors have recently modified their holdings of the company. First Mercantile Trust Co. purchased a new stake in shares of bluebird bio during the third quarter worth approximately $129,000. Advantage Investment Management LLC purchased a new stake in shares of bluebird bio during the fourth quarter worth approximately $159,000. Sei Investments Co. increased its stake in shares of bluebird bio by 106.7% in the third quarter. Sei Investments Co. now owns 2,515 shares of the company’s stock worth $170,000 after buying an additional 1,298 shares during the period. Winslow Evans & Crocker Inc. increased its stake in shares of bluebird bio by 170.0% in the third quarter. Winslow Evans & Crocker Inc. now owns 2,700 shares of the company’s stock worth $183,000 after buying an additional 1,700 shares during the period. Finally, Advisor Group Inc. increased its stake in shares of bluebird bio by 482.2% in the third quarter. Advisor Group Inc. now owns 2,783 shares of the company’s stock worth $188,000 after buying an additional 2,305 shares during the period.

About bluebird bio

bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).

5 Day Chart for NASDAQ:BLUE

Receive News & Ratings for bluebird bio Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Nike Suspends Relationship with Maria Sharapova
Nike Suspends Relationship with Maria Sharapova
Rob Bironas Ex-Titans Kicker Dies in Car Crash
Rob Bironas Ex-Titans Kicker Dies in Car Crash
Ron Washington Leaves Texas Rangers Due to an Affair
Ron Washington Leaves Texas Rangers Due to an Affair
Jonathan Dwyer Falls in Line with Other Banned NFL Players
Jonathan Dwyer Falls in Line with Other Banned NFL Players
Tony Stewart Case Going to the Grand Jury
Tony Stewart Case Going to the Grand Jury
Oscar Pistorius “Blade Runner” Found Not Guilty of Murder
Oscar Pistorius “Blade Runner” Found Not Guilty of Murder


Leave a Reply

 
© 2006-2017 Web Breaking News.